Lexeo Therapeutics’ (LXEO) Overweight Rating Reiterated at Cantor Fitzgerald

Lexeo Therapeutics (NASDAQ:LXEO)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports.

LXEO has been the subject of a number of other reports. Leerink Partners restated an “outperform” rating and issued a $15.00 price target on shares of Lexeo Therapeutics in a research note on Wednesday, September 23rd. Wall Street Zen upgraded Lexeo Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday. Raymond James Financial reissued a “strong-buy” rating on shares of Lexeo Therapeutics in a report on Tuesday, September 22nd. Finally, Chardan Capital raised shares of Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $16.43.

Lexeo Therapeutics Trading Up 0.3%

LXEO opened at $3.07 on Thursday. The stock has a market capitalization of $251.89 million, a P/E ratio of -2.67 and a beta of 1.64. Lexeo Therapeutics has a 12 month low of $2.55 and a 12 month high of $10.99. The firm’s fifty day simple moving average is $3.46 and its 200 day simple moving average is $5.05.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.01). On average, equities research analysts predict that Lexeo Therapeutics will post -1.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds have recently bought and sold shares of the company. Aberdeen Group plc increased its position in Lexeo Therapeutics by 90.5% during the third quarter. Aberdeen Group plc now owns 1,286,077 shares of the company’s stock worth $4,347,000 after buying an additional 610,985 shares during the last quarter. Signaturefd LLC lifted its position in shares of Lexeo Therapeutics by 5,159.1% in the third quarter. Signaturefd LLC now owns 8,362 shares of the company’s stock valued at $28,000 after buying an additional 8,203 shares during the last quarter. Abel Hall LLC bought a new position in shares of Lexeo Therapeutics during the 3rd quarter worth approximately $43,000. Spark Investment Management LLC bought a new position in shares of Lexeo Therapeutics during the 2nd quarter worth approximately $70,000. Finally, Frazier Life Sciences Management L.P. boosted its stake in shares of Lexeo Therapeutics by 9.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,824,725 shares of the company’s stock worth $22,459,000 after acquiring an additional 400,000 shares during the period. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.